For the Person in Every Patient
One of the most serious GI diseases is Inflammatory Bowel Disease (IBD), a complex and heterogeneous condition. Today, a variety of medications and modifications to treatment regimens are needed to achieve optimal outcomes – Prometheus Biosciences will change this. We are developing novel therapeutics and companion tests to provide the right drug for the right patient.
Translating Science into Therapeutics and Diagnostics
Our approach to IBD incorporates comprehensive clinical and research metadata from a biorepository of over 20,000 patients to decipher the dominant disease biology in subgroups of patients. For each of these subgroups we identify novel drug targets and tests to predict response to these therapies. LEARN MORE
Our Scientific Foundation
Prometheus Biosciences is a biopharmaceutical company focused on the discovery and development of a broad portfolio of precision therapeutics and companion diagnostics for gastrointestinal (GI) diseases and disorders. Prometheus has an extensive clinical biobank with paired longitudinal medical records that has enabled identification of novel targets for treatment of patients with biomarker-defined subclinical GI phenotypes.